Pulmonary complications of targeted therapy -Immune checkpoint inhibitors (e.g. pembrolizumab) -Pneumonitis is uncommon (~5% of patients) but can be severe. -It’s a diagnosis of exclusion: rule out infection and malignancy-associated pnuemonitis, as well as radiation pneumonitis. -Can occur at any time during therapy. -1/3 of patients are asymptomatic, and the most common presenting symptom is cough -Imaging characteristics vary widely. There are case reports of pleural effusion associated with a clinical diagnosis pneumonitis, but it’s unclear if this is a drug side effect or a “reactive” response to cancer cell death in response to therapy. #Clinical #Diagnosis #Radiology #Honc #CheckpointInhibitors #PulmonaryComplications #Patterns
